share_log

HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target

Benzinga ·  May 25 00:48

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment